LX4211, a Dual Inhibitor of SGLT2 and SGLT1 Enhances the Effects of Sitagliptin in Patients With Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Zambrowicz, Brian
Ogbaa, Ike
Powell, David
Banks, Phillip
Turnage, Anne
Frazier, Kenny
Boehm, Kristi A.
Freiman, Joel
Lapuerta, Pablo
Sands, Arthur
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
974-P
引用
收藏
页码：A248 / A249
页数：2
相关论文
共 50 条
  • [1] LX4211, a dual inhibitor of SGLT2 and SGLT1 enhances the effects of sitagliptin in patients with type 2 diabetes mellitus
    Zambrowicz, B.
    Ogbaa, I.
    Powell, D.
    Banks, P.
    Turnage, A.
    Frazier, K.
    Boehm, K. A.
    Freiman, J.
    Lapuerta, P.
    Ruff, D.
    Sands, A.
    DIABETOLOGIA, 2012, 55 : S318 - S318
  • [2] Discovery and development of LX4211, a dual inhibitor of SGLT1 and SGLT2 for the treatment of type 2 diabetes mellitus
    Rawlins, David B.
    Frazier, Kenny S.
    Freiman, Joel
    Goodwin, Nicole C.
    Harrison, Bryce A.
    Healy, Jason
    Mabon, Ross
    Powell, David R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [3] LX4211, a Dual SGLT1/SGLT2 Inhibitor Shows a Favorable Gastrointestinal and Genitourinary Safety Profile in Type 2 Diabetes Mellitus (T2DM) Patients and Healthy Subjects
    Freiman, Joel
    Ye, Gui-Lan
    Ogbaa, Ike
    Boehm, Kristi A.
    Turnage, Anne
    Frazier, Kenny
    Sands, Arthur
    Zambrowicz, Brian
    DIABETES, 2012, 61 : A255 - A255
  • [4] Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes
    Zambrowicz, Brian
    Ding, Zhi-Ming
    Ogbaa, Ike
    Frazier, Kenny
    Banks, Phillip
    Turnage, Anne
    Freiman, Joel
    Smith, Melinda
    Ruff, Dennis
    Sands, Arthur
    Powell, David
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 273 - 285
  • [5] LX4211, a Dual SGLT1/SGLT2 Inhibitor, Decreases Body Weight and Triglycerides in Patients With Type 2 Diabetes Mellitus and Elevated Baseline Values
    Zambrowicz, Brian
    Lapuerta, Pablo
    Ogbaa, Ike
    Banks, Phillip
    Frazier, Kenny
    Boehm, Kristi A.
    Kelly, Mike
    Sands, Arthur
    DIABETES, 2013, 62 : A62 - A62
  • [6] LX4211, a dual inhibitor of SGLT1/SGLT2, reduces postprandial glucose in patients with type 2 diabetes mellitus and moderate to severe renal impairment
    Lapuerta, P.
    Sands, A.
    Ogbaa, I.
    Strumph, P.
    Powell, D.
    Banks, P.
    Zambrowicz, B.
    DIABETOLOGIA, 2014, 57 : S324 - S324
  • [7] LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, reduces blood pressure in patients with type 2 diabetes
    Lapuerta, P.
    Neutel, J.
    Zambrowicz, B.
    Ogbaa, I.
    Banks, P.
    Frazier, K.
    Sands, A.
    DIABETOLOGIA, 2013, 56 : S380 - S380
  • [8] LX4211, a dual SGLT1/SGLT2 inhibitor, decreases body weight and triglycerides in patients with type 2 diabetes mellitus and elevated baseline values
    Zambrowicz, B.
    Lapuerta, P.
    Ogbaa, I.
    Banks, P.
    Frazier, K.
    Boehm, K. A.
    Kelly, M.
    Sands, A.
    DIABETOLOGIA, 2013, 56 : S399 - S399
  • [9] The Impact of LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, on Blood Pressure in Patients With Type 2 Diabetes
    Lapuerta, Pablo
    Neutel, Joel
    Zambrowicz, Brian
    Ogbaa, Ike
    Banks, Phillip
    Frazier, Kenny
    Sands, Arthur
    DIABETES, 2013, 62 : A62 - A62
  • [10] LX4211, a dual SGLT1/SGLT2 inhibitor shows a favourable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus patients and healthy subjects
    Freiman, J.
    Ye, G. -L.
    Ogbaa, I.
    Boehm, K. A.
    Turnage, A.
    Frazier, K.
    Sands, A.
    Zambrowicz, B.
    DIABETOLOGIA, 2012, 55 : S318 - S319
12345